Department of Cardiovascular Medicine, University Hospitals Leuven and Department of Cardiovascular Sciences, Katholieke Universiteit Leuven, Leuven, Belgium.
Cardiology Division ASST Bergamo Est, Seriate and lnterventional Cardiology Unit, Istituto Clinico Sant'Ambrogio, Milan, Italy.
Cardiovasc Revasc Med. 2022 Jun;39:106-113. doi: 10.1016/j.carrev.2021.09.012. Epub 2021 Oct 1.
Bioresorbable scaffolds provide transient vessel support without the long-term limitations of permanent metallic drug-eluting stents. The sirolimus-eluting resorbable magnesium scaffold Magmaris is the only CE-marked metallic bioresorbable scaffold and provides short-term lumen support before being completely bioresorbed. To date, clinical trial results have demonstrated low adverse event rates in patients with simple coronary lesions. Seven European centers with large experience in Magmaris implantation, combined efforts in an informal collaboration to evaluate and appraise clinical data currently available regarding the performance of Magmaris in patients presenting with acute coronary syndromes, and to supply user-advice on patient selection and optimal implantation practice.
生物可吸收支架可提供短暂的血管支撑,而不会产生永久性金属药物洗脱支架的长期局限性。西罗莫司洗脱可吸收镁支架 Magmaris 是唯一获得 CE 标志的金属生物可吸收支架,在完全可吸收之前可提供短期管腔支撑。迄今为止,临床试验结果表明,简单冠状动脉病变患者的不良事件发生率较低。7 个欧洲中心在 Magmaris 植入方面拥有丰富的经验,他们联合起来进行了一项非正式合作,以评估和评估目前关于 Magmaris 在急性冠状动脉综合征患者中的性能的临床数据,并就患者选择和最佳植入实践提供用户建议。